Selpercatinib
- Generic Name
- Selpercatinib
- Brand Names
- Retevmo, Retsevmo
- Drug Type
- Small Molecule
- Chemical Formula
- C29H31N7O3
- CAS Number
- 2152628-33-4
- Unique Ingredient Identifier
- CEGM9YBNGD
- Background
Selpercatinib is a kinase inhibitor with enhanced specificity for RET tyrosine kinase receptors (RTKs) over other RTK classes. Enhanced RET (Rearranged during transfection) oncogene expression is a hallmark of many cancers. Although multikinase inhibitors, including cabozantinib, ponatinib, sorafenib, sunitinib, and vandetanib, have shown efficacy in RET-dri...
- Indication
Selpercatinib is approved to treat:
Selpercatinib is currently approved for these indications under an accelerated approval scheme and continued approval may be contingent on future confirmatory trials.
- Associated Conditions
- Locally Advanced Solid Neoplasm, Metastatic Solid Neoplasm, Advanced RET-fusion thyroid cancer, Advanced RET-mutant medullary thyroid cancer, Metastatic RET-fusion Non Small Cell Lung Cancer, Metastatic RET-fusion thyroid cancer, Metastatic RET-mutant medullary thyroid cancer
- Associated Therapies
- -
Targeted Therapy Directed by Genetic Testing in Treating Pediatric Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphomas, or Histiocytic Disorders (The Pediatric MATCH Screening Trial)
- Conditions
- Interventions
- Procedure: BiopsyProcedure: Biospecimen CollectionOther: Laboratory Biomarker AnalysisProcedure: Bone Marrow Aspiration and BiopsyDrug: Larotrectinib SulfateProcedure: Bone ScanProcedure: Mutation Carrier ScreeningOther: Pharmacological StudyProcedure: Computed TomographyDrug: OlaparibDrug: PalbociclibDrug: Selumetinib SulfateDrug: TipifarnibDrug: ErdafitinibDrug: TazemetostatDrug: SamotolisibDrug: EnsartinibDrug: VemurafenibDrug: UlixertinibProcedure: Magnetic Resonance ImagingDrug: SelpercatinibProcedure: Positron Emission TomographyProcedure: Radionuclide ImagingProcedure: X-Ray Imaging
- First Posted Date
- 2017-05-16
- Last Posted Date
- 2024-12-16
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 2316
- Registration Number
- NCT03155620
- Locations
- 🇺🇸
Duke University Medical Center, Durham, North Carolina, United States
🇺🇸East Carolina University, Greenville, North Carolina, United States
🇺🇸Wake Forest University Health Sciences, Winston-Salem, North Carolina, United States
The Drug Rediscovery Protocol (DRUP Trial)
- Conditions
- Interventions
- Drug: PanitumumabDrug: OlaparibDrug: CrizotinibDrug: ErlotinibDrug: AlectinibDrug: Ipilimumab and nivolumabDrug: SunitinibDrug: Trastuzumab and Pertuzumab (combination treatment)Drug: Vemurafenib and Cobimetinib (combination treatment)Drug: NivolumabDrug: Dabrafenib and trametinibDrug: SelpercatinibDrug: TepotinibDrug: AbemaciclibDrug: ErdafitinibDrug: Atezolizumab and BevacizumabDrug: DacomitinibDrug: DabrafenibDrug: NilotinibDrug: TrametinibDrug: VismodegibDrug: RegorafenibDrug: AfatinibDrug: RibociclibDrug: LenvatinibDrug: PembrolizumabDrug: DurvalumabDrug: RucaparibDrug: AxitinibDrug: PalbociclibDrug: CabozantinibDrug: EntrectinibDrug: TalazoparibDrug: LorlatinibDrug: AlpelisibDrug: NiraparibDrug: Pemigatinib
- First Posted Date
- 2016-10-05
- Last Posted Date
- 2024-01-24
- Lead Sponsor
- The Netherlands Cancer Institute
- Target Recruit Count
- 1550
- Registration Number
- NCT02925234
- Locations
- 🇳🇱
Meander medisch centrum, Amersfoort, Netherlands
🇳🇱Netherlands Cancer Institute, Amsterdam, Netherlands
🇳🇱Amsterdam UMC, locatie AMC, Amsterdam, Netherlands
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.